Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-13
2007-02-13
Wilson, Michael (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210, C435S455000, C435S459000, C435S470000
Reexamination Certificate
active
08931219
ABSTRACT:
The present invention relates to various methods of genetic immunization for the purpose of providing antigen-specific immunity in a mammalian host, including a human host. The invention is based on the ability to direct particulate polynucleotides which express an antigenic protein or protein fragment to the cytoplasm of host target cells, such as antigen presenting cells. A directed delivery of such particulate polynucleotides to the cytoplasm of antigen presenting cells will stimulate antigen-specific CTL production, thus promoting destruction of affected cells such as neoplastic cells and virally infected cells.
REFERENCES:
patent: 5593972 (1997-01-01), Weiner et al.
patent: 2002/0054864 (2002-05-01), Falo et al.
Schofield and Caskey, British Medical Bulletin, vol. 51, pp. 56-71, 1995.
Marshall, Science, vol. 269, pp. 1050-1055, Aug. 25, 1995.
Coghlan, Focus, vol. 145, pp. 14-15, Nov. 25, 1995.
Brown, The Washington Post, Dec. 8, 1995.
Bignon et al., European Journal of Dermatology, vol. 6, pp. 159-163, 1996.
Cournoyer and Caskey, Annu. Rev. Immunol., vol. 11, pp. 297-329, 1993.
Hanania et al., American Journal of Medicine, vol. 99, pp. 537-552, Nov. 1995.
Orkin and Motulsky, Report and Recommendation of the Panel . . . Gene Therapy, Dec. 7, 1995.
Nabel et al., Human Gene Therapy, vol. 3, pp. 399-410, 1992.
Eisenbraun et al., DNA Cell Biol., vol. 12, pp. 791-797, 1993.
Robinson et al., Vaccine, vol. 11, pp. 957-960, 1993.
Nakano et al., Journal of Virology, vol. 71, pp. 7101-7109, Sep. 1997.
Culver et al., British Medical Bulletin, vol. 5, pp. 192-204, Jan. 1995.
Barry et al., Vaccine, vol. 15, pp. 788-791, 1997.
Tang et al., Nature, vol. 356, pp. 152-154, Mar. 12, 1992.
Barry et al., Biotechniques, vol. 16, pp. 616-618, Apr. 1994.
Hui et al., Journal of Immunological Methods, vol. 171, pp. 147-155, May 16, 1994.
Whalen et al., Clinical Immunology and Immunopathology, vol. 75, pp. 1-12, Apr. 1995.
Boon et al., Annual Review of Immunology, vol. 12, pp. 337-365, 1994.
Kawakami et al., Journal of Immunology, vol. 154, pp. 3961-3968, Apr. 15, 1995.
Frey et al., Clinical Immunology and Immunopathology, vol. 69, pp. 223-233, Nov. 1993.
Appleman et al., International Journal of Cancer, vol. 61, pp. 887-894, Jun. 9, 1995.
Johnston et al., Methods in Cell Biology, vol. 43, pp. 353-365, 1994.
Klein et al., Current Opinion in Biotechnology, vol. 4, pp. 583-590, Oct. 1993.
Fundamental Immunology, William E. Paul, Raven Press: New York, Third Edition, pp. 121 & 593, 1993.
Miller (1995, FASEB J., vol. 9, pp. 190-199).
Deonarain (1998, Expert Opin. Ther. Pat., vol. 8, p. 53-69).
Verma (Sep. 1997, Nature, vol. 389, pp. 239-242).
Crystal (1995, Science, vol. 270, p. 404-410).
Stricker (Medical Hypotheses, Jun. 1997, vol. 48, pp. 527-529).
Bangham, Nov. 29, 1997, Lancet, vol. 350, pp. 1617-1621.
Veljkovic (Vaccine, 2001, vol. 19, p. 1855-1862).
McMichael, Annual Rev. Immunol., 1997, vol. 15, p. 271-296.
Weber (Eur. J. Clin. Microbiol. Infect. Dis., Nov. 2001, vol. 20, p. 800-803).
Webster (Vaccine, Dec. 1994, vol. 12, No. 16, p. 1495-1498).
Robinson (Seminars in Immunology, 1997, vol. 9, p. 271-283).
Kuby (Immunology, 1992, W.H. Freeman and Company, New York, p. 208).
Peachman (Methods, 2003, vol. 31, p. 232-242).
Haynes (AIDS research and human retroviruses, 1994, vol. 10, Supplement 2, p. S43-45).
Haynes (Vaccine, 1994, Cold Spring Harbor, Modern approaches to new vaccines including prevention of AIDS, p. 65-70).
Lai (DNA and cell biology, Jul. 1995, vol. 14, No. 7, p. 643-651).
Hui (J. Immunological Methods, May 16, 1994, vol. 171, p. 147-155).
Johnston (Methods in cell Biology, 1994, vol. 43, Chapt, 14, p. 353-365).
Shiver (Advanced Drug Delivery Rev., 1996, vol. 21, p. 19-31).
Larregina (Gene Therapy, 2001, vol. 8, p. 608-617).
Tuting (J. Invest. Dermatol., 1998, vol. 111, p. 183-188).
Dorlands Medical Dictionary page showing the cross section of the skin.
Dorlands Medical Dictionary definition of Langerhans cells.
Barry (1994, BioTechniques, vol. 16, No. 4, p. 616-618).
Fuller (AIDS Research and Human Retroviruses, Nov. 1994, vol. 10, No. 11, p. 1433-1441).
Falo, Jr. Louis D.
Rock Kenneth L.
Dana-Farber Cancer Institute
Foley & Lardner LLP
The University of Pittsburgh of the Commonwealth System of Highe
Wilson Michael
LandOfFree
Stimulation of cell-mediated immune responses by targeted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stimulation of cell-mediated immune responses by targeted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stimulation of cell-mediated immune responses by targeted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823300